ANNX

Annexon Inc

ANNX.US annexonbio.com + Research + Basket
CIK 0001528115
Employees 92
Phone 650 822 5500
Fiscal year end December
IPO Jul 24, 2020
Address 1400 Sierra Point Parkway, Brisbane, CA, United States, 94005
4.04
+0.28 (+7.45%)
USD · NASDAQ
52-week range
2.54
7.18
Trading at 32% of the 52-week range
Market Cap
712.82M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
1.07
Div. Yield
N/A
% Institutions
103.45%
% Insiders
0.438%

1 Year

+17.1%

3 Year

+77.2%

10 Year

-77.3%
Description

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Actions

Add an action for ANNX.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Douglas E. Love Esq., J.D. CEO, President & Director 1968
Ms. Jennifer Lew CPA Executive VP, CFO & Corporate Secretary 1973
Dr. Ted Yednock Ph.D. Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board 1958
Dr. Dean R. Artis Ph.D. Chief Scientific Officer & Executive VP 1961
Ms. Linda A. Fitzpatrick Chief Human Resources Officer 1957
Mr. Michael Overdorf M.B.A. Executive VP & Chief Business Officer 1971
Mr. Henk-Andre Kroon M.D. Senior Vice President of Translational Medicine NA
Dr. Jamie Dananberg M.D. Executive VP & Chief Medical Officer 1958
Mr. Shikhar Agarwal M.B.A. Senior VP & Head of Commercial NA
Dr. Sunil Mehta Pharm.D. Senior VP of Medical Affairs NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Apr 10, 2026 William H Carson N/A Purchase 8.00K $6.20 $49.60K SEC
Mar 10, 2026 William H Carson N/A Purchase 8.00K $5.67 $45.36K SEC
Feb 18, 2026 Dean Richard Artis N/A Sale 5.29K $5.10 $26.98K SEC
Feb 18, 2026 Jamie Dananberg N/A Sale 5.29K $5.10 $26.98K SEC
Feb 18, 2026 Jennifer Lew N/A Sale 7.85K $5.11 $40.12K SEC
Feb 18, 2026 Michael Overdorf N/A Sale 6.23K $5.10 $31.75K SEC
Feb 18, 2026 Ted Yednock N/A Sale 7.86K $5.11 $40.15K SEC
Dec 30, 2025 William H Carson N/A Purchase 4.12K $5.02 $20.66K SEC
Dec 01, 2025 Jung Choi N/A Purchase 33.00K $4.19 $138.27K SEC
Dec 01, 2025 William H Carson N/A Purchase 4.12K $4.47 $18.39K SEC
Nov 21, 2025 Muneer A Satter N/A Purchase 422.61K $4.28 $1.81M SEC
Nov 20, 2025 Muneer A Satter N/A Purchase 400.00K $4.48 $1.79M SEC
Nov 19, 2025 Muneer A Satter N/A Purchase 500.00K $3.94 $1.97M SEC
Nov 17, 2025 Muneer A Satter N/A Purchase 500.00K $2.99 $1.50M SEC
Oct 30, 2025 William H Carson N/A Purchase 4.12K $3.17 $13.04K SEC
Sep 30, 2025 William H Carson N/A Purchase 4.12K $3.05 $12.55K SEC
Jul 30, 2025 William H Carson N/A Purchase 4.12K $2.43 $10.00K SEC
Jul 14, 2025 Jennifer Lew N/A Sale 1.12K $2.58 $2.88K SEC
Jul 14, 2025 Jennifer Lew N/A Sale 1.12K $2.58 $2.88K SEC
Jul 14, 2025 Michael Overdorf N/A Sale 853.00 $2.61 $2.23K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 19.52M Jun 30, 2026 10.30% $0.00 83.52%
BlackRock Inc 13.54M Jun 30, 2026 7.14% $0.00 23.78%
Redmile Group, LLC 11.87M Jun 30, 2026 6.26% $4.55 -18.42%
State Street Corp 9.82M Jun 30, 2026 5.18% $0.00 41.99%
Bvf Inc 8.70M Jun 30, 2026 4.59% $1.27 0.00%
Woodline Partners LP 6.93M Jun 30, 2026 3.65% $0.12 196.31%
Vanguard Capital Management, LLC 6.87M Jun 30, 2026 3.62% $0.00 15.35%
Mak Capital One LLC 5.86M Jun 30, 2026 3.09% $4.69 24.09%
The Goldman Sachs Group Inc 5.83M Jun 30, 2026 3.07% $0.00 170.59%
Siren, L.L.C. 4.46M Jun 30, 2026 2.35% $0.52 12.63%
Bain Capital Life Sciences Investors, LLC 4.44M Jun 30, 2026 2.34% $1.51 -14.87%
Bellevue Group AG 4.10M Jun 30, 2026 2.16% $0.49 -20.50%
Geode Capital Management, LLC 4.04M Jun 30, 2026 2.13% $0.00 19.52%
MPM Oncology Impact Management LP 3.54M Jun 30, 2026 1.87% $1.23 0.00%
Ameriprise Financial Inc 3.51M Jun 30, 2026 1.85% $0.00 1.75%
Great Point Partners LLC 3.50M Jun 30, 2026 1.85% $3.78 40.00%
Adage Capital Partners Gp LLC 3.50M Jun 30, 2026 1.85% $0.03 -18.60%
Morgan Stanley - Brokerage Accounts 3.14M Jun 30, 2026 1.66% $0.00 14.93%
Palo Alto Investors, LLC 2.95M Jun 30, 2026 1.56% $2.33 0.00%
Balyasny Asset Management LLC 2.83M Jun 30, 2026 1.49% $0.02 -27.17%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Select Biotechnology 6.17M 3.26% ▲ 0.00% Aug 31, 2026
2 State Street® SPDR® S&P® Biotech ETF 5.89M 3.10% ▼ 1.88% Sep 30, 2026
3 Vanguard MStar Total Stk Mkt Idx Invest 5.72M 3.02% ▲ 15.10% Sep 30, 2026
4 iShares Russell 2000 ETF 4.08M 2.15% ▼ 1.14% Sep 30, 2026
5 Fidelity Stock Selector Small Cap 2.07M 1.09% ▲ 27.57% Jul 31, 2026
6 Columbia Acorn Inst 1.82M 0.96% ▲ 0.00% Aug 31, 2026
7 Fidelity Small Cap Growth 1.79M 0.94% ▲ 44.14% Jul 31, 2026
8 Fidelity Small Cap Index 1.70M 0.89% ▲ 0.70% Jul 31, 2026
9 Fidelity Advisor Biotechnology I 1.66M 0.88% ▲ 0.00% Aug 31, 2026
10 iShares Russell 2000 Growth ETF 1.47M 0.78% ▼ 0.13% Sep 30, 2026

Financial Highlights

▼
Market Cap: $712.82M
EBITDA: $-208.39M
Book Value: $1.07
Earnings/Share: $-1.13
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -51.54%
ROE (TTM): -105.26%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $516.85M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 189.58M
Shares Float: 163.76M
% Insiders: 0.438%
% Institutions: 103.45%
Short % Float: 17.87%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-3.69M
Gross Profit
subtotal
$-3.69M
SG&A
adjust
$-31.71M
R&D
adjust
$-184.70M
Operating Income
subtotal
$-216.41M
Other / Non-Operating Items
adjust
$9.72M
Net Income
subtotal
$-206.69M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ANNX.US!